Disclosure of shareholdings in accordance with Art. 20 SESTA

12 november 2007 Santhera Pharmaceuticals Holding AG (SWX:SANN) was informed by NGN BioMed I GP, L.P. and NGN Capital LLC, 369 Lexington Avenue, 17th floor, New York, NY 10017, U.S. that the following funds under their management - NGN BioMed Opportunity I L.P. - NGN BioMed Opportunity I GmbH + Co. Beteiligungs KG together hold 379,102 shares of Santhera Pharmaceuticals Holding AG, representing 12.23% of the voting rights of the shares registered in the Commercial Register. Merlin General Partner II Ltd, La Motte Chambers, La Motte Street, St. Helier, Jersey that the following funds under its management - Merlin Biosciences Fund LP - Merlin Biosciences Fund GbR together hold 239,592 shares of Santhera Pharmaceuticals Holding AG, representing 7.73% of the voting rights of the shares registered in the Commercial Register. OBP Management III, L.P., OBP Management (Bermuda) III and mRNA Partners, L.P., 222 Berkeley Street, Suite 1650, Boston, MA 02116, U.S. that the following funds under their management - Oxford Bioscience Partners III L.P. - Oxford Bioscience Partners (Bermuda) III Limited Partnership - Oxford Bioscience Partners (Adjunct) III L.P. - mRNA Fund L.P. together hold 220,090 shares of Santhera Pharmaceuticals Holding AG, representing 7.10% of the voting rights of the shares registered in the Commercial Register. 3i Investments plc, 16 Palace Street, London SW1 E5JD, UK that the following fund under its management - 3i Group plc holds 213,278 shares of Santhera Pharmaceuticals Holding AG, representing 6.88% of the voting rights of the shares registered in the Commercial Register. In addition, Santhera Pharmaceuticals Holding AG was notified by the above shareholders that their lock-up undertaking vis-a-vis Deutsche Bank has expired and that as a consequence thereof, they no longer form a "group acting in concert" (Group) within the meaning of Article 20 of the Swiss Federal Stock Exchange Act as disclosed in Santhera's Offering Memorandum dated November 2, 2006. The other members of the Group were: GIMV NV, BE-Antwerp, Adviesbeheer, GIMV Life Sciences NV, BE-Antwerp, Varuma AG, CH-Basel, Heidelberg Innovation GmbH, DE-Heidelberg, Heidelberg Innovation GmbH & Co. BioScience Venture KG (BSV I), DE-Heidelberg, Heidelberg Innovation Fonds Management GmbH, DE-Heidelberg, Heidelberg Innovation BioScience Venture II GmbH & Co. KG (BSV II), DE-Heidelberg, Heidelberg Innovation Parallel-Beteiligungs GmbH & Co. KGaA, DE-Heidelberg, Carnegie Fund Management Company SA, LU-Luxembourg, Carnegie Fund II Biotechbridge Sub Fund, LU-Luxembourg, Clariden Biotechnology Equity Fund, CH-Zürich, Clariden Bank, Biotechnology Fund, CH-Zürich, Schweizerische Stiftung für die Erforschung der Muselkrankheiten, CH-Bern, Dow Europe GmbH, CH-Horgen, The Dow Chemical Company, US-Midland, MI 48674, Altana Innovationsfonds GmbH, DE-Konstanz, Nachlass Karin Müller, CH-Zürich, Dobler Dr. Ernst-Ulrich, DE-Freiburg, Wolf Dr. Peter, CH-Pratteln, Hofbauer Prof. Karl, CH-Basel, Rüegg Prof. Markus, CH-Riehen, NeoMed Management (Jersey) Ltd., JE-St. Helier, NeoMed Innovation IV, JE-St. Helier, BioMedinvestor AG, CH-Basel, BioMedinvest AG, CH-Basel, TechnoStart Ventures Verwaltungs GmbH, DE-Ludwigsburg, TechnoStart Ventures GmbH & Co. Fonds KG, DE-Ludwigsburg, Zweite TechnoStart Ventures Verwaltungs GmbH, DE-Ludwigsburg, Zweite TechnoStart Ventures GmbH & Co. KG, DE-Ludwigsburg, Novartis Forschungsstiftung c/o Novartis International AG, CH-Basel. * * * For further information, contact Thomas Staffelbach, VP Public & Investor Relations Phone: +41 (0)61 906 89 47 thomas.staffelbach@santhera.com --- End of Message --- Santhera Pharmaceuticals Holding AG Hammerstrasse 47 Liestal Switzerland WKN: A0LCUK; ISIN: CH0027148649; Index: SPI, SPIEX, SSCI; Listed: Main Market in SWX Swiss Exchange;